Who holds it, who is betting against it, and where the big money is moving
Net of large-order buying minus selling, in USD. Over this window: −$2.60M (13 inflow days, 7 outflow days).
Super/Big orders approximate institutional-size trades; Mid/Small approximate retail-size trades. Net buy minus sell value in each bucket, summed over the window.
The five largest holders on file together own 41.2% of shares outstanding.
Reported short interest has fallen from 13.32% to 9.17% of float over the last 6 biweekly reports (30 Jun 2026 to 15 Sep 2026).
| Date | Insider | Title | Transaction | Shares | Price | Held after |
|---|---|---|---|---|---|---|
| 7 Aug 2024 | Artal Group S.A. | Open Market Disposition | -322,361 | $0.19 | 6,317,565 | |
| 5 Aug 2024 | Artal Group S.A. | Open Market Disposition | -220,255 | $0.19 | 6,639,926 | |
| 1 Aug 2024 | Artal Group S.A. | Open Market Disposition | -349,764 | $0.22 | 6,860,181 | |
| 29 Jul 2024 | Artal Group S.A. | Open Market Disposition | -1,379,119 | $0.24 | 7,209,945 | |
| 24 Jul 2024 | Artal Group S.A. | Initial Statement of Beneficial | +0 | – | 8,589,064 | |
| 20 Jun 2024 | Edwin Rock | Senior VP & Chief Medical Officer | Open Market Acquisition | +305,000 | $0.27 | 680,403 |
| 17 Jun 2024 | Brian Hahn | Senior Vice President | Open Market Acquisition | +17,500 | $0.25 | 62,018 |
| 30 Apr 2024 | Daniel Junius | Independent Director | Other Derivative Acquisition | +40,000 | $1.62 | 40,000 |
| 30 Apr 2024 | Mark Goldberg | Other Derivative Acquisition | +40,000 | $1.62 | 40,000 | |
| 30 Apr 2024 | Timothy Pearson | Independent Chairperson | Other Derivative Acquisition | +40,000 | $1.62 | 40,000 |
| 30 Apr 2024 | Scott Koenig | Independent Director | Other Derivative Acquisition | +40,000 | $1.62 | 40,000 |
| 30 Apr 2024 | Rachel King | Co-Founder | Other Derivative Acquisition | +40,000 | $1.62 | 40,000 |
| 30 Apr 2024 | Scott Jackson | Independent Director | Other Derivative Acquisition | +40,000 | $1.62 | 40,000 |
| 30 Apr 2024 | Patricia Susan Andrews | Independent Director | Other Derivative Acquisition | +40,000 | $1.62 | 40,000 |
| 28 Mar 2024 | Daniel Junius | Independent Director | Other Acquisition | +5,209 | $3.00 | 98,459 |
| 28 Mar 2024 | Mark Goldberg | Other Acquisition | +4,584 | $3.00 | – | |
| 28 Mar 2024 | Rachel King | Co-Founder | Other Acquisition | +3,334 | $3.00 | 635,033 |
| 11 Jan 2024 | Brian Hahn | Senior Vice President | Other Derivative Acquisition | +250,000 | $3.11 | 250,000 |
| 11 Jan 2024 | Harout Semerjian | Chief Executive Officer | Other Derivative Acquisition | +695,000 | $3.11 | 695,000 |
| 11 Jan 2024 | Edwin Rock | Senior VP & Chief Medical Officer | Other Derivative Acquisition | +250,000 | $3.11 | 250,000 |
From Form 4/Form 144 filings. Negative share counts are disposals (sales, gifts, or shares withheld for taxes); positive are acquisitions.
| Report date | Shares short | % of float | Days to cover |
|---|---|---|---|
| 15 Sep 2026 | 3,407,158 | 9.2% | 8.5 |
| 31 Aug 2026 | 3,172,374 | 8.5% | 19.9 |
| 14 Aug 2026 | 3,216,698 | 8.7% | 17.1 |
| 31 Jul 2026 | 3,465,334 | 9.3% | 8.9 |
| 15 Jul 2026 | 3,743,278 | 13.6% | 9.7 |
| 30 Jun 2026 | 3,673,343 | 13.3% | 7.0 |
No comments yet — be the first to weigh in on CBIO.